P-Values

May 8, 2026 The US administration again blocks key vaccine safety and effectiveness data; a hantavirus incident underscores growing strain and fragmentation in the global health system; and Zambia rejects a “trade for aid” deal tying health assistance to geopolitical and economic interests—with implications for HIV programs and global health cooperation. The US Administration continues to block publication of key vaccine safety and effectiveness data.

May 4, 2026 Join us Wednesday, May 20 at 10am ET for a conversation with Nicholas Enrich, author of Into the Wood Chipper and former global health lead at the US Agency for International Development (USAID). Inside the Decisions that Changed Global Health will provide Enrich’s inside perspective on the decisions that led to the dismantling of USAID and the foreign aid freeze and what they mean for global health today.

May 1, 2026 On the heels of the recent PEPFAR data release, a New York Times article by Stephanie Nolen, AIDS Creeps Back in Parts of Zambia, a Year After US Cuts to HIV Assistance, this week serves as an illustration of the consequences of the US policy decisions on lives. It shows what the policy shifts, funding disruptions, and data gaps covered in this issue, look like in Zambia: strained clinics, interrupted HIV services, and uncertainty for patients and providers relying on PEPFAR.

April 29, 2026 The International Conference on HIV Treatment, Pathogenesis, and Prevention Research (INTEREST), will take place 12-15 May in Dar es Salaam, Tanzania, covering new advances in HIV prevention, treatment, cure, and vaccine research and development (R&D); implementation science; and how science is being translated into impact through an African-led HIV agenda. AVAC has compiled resources and highlights to support participation and engagement.

April 27, 2026 Newly released data from the President’s Emergency Plan for AIDS Relief (PEPFAR) were meant to reassure, but a deeper look tells a more concerning story. AVAC’s latest blog post and graphics provide a more nuanced analysis: “Reduced prevention today means higher HIV incidence in the future.

April 24, 2026 By Mitchell Warren and Suraj Madoori For more than two decades, the President’s Emergency Plan for AIDS Relief (PEPFAR) has been widely recognized as one of the most effective global health programs in history—saving lives, strengthening health systems, and building a durable HIV response that, with consistent bipartisan support, has weathered global disruptions and crises from Ebola to COVID-19.

April 24, 2026 Newly released PEPFAR data reveals declines in HIV testing and prevention; a new report details the impact of US funding cuts on HIV programs in South Africa; and the US Centers for Disease Control and Prevention (CDC) blocks publication showing the benefits of COVID-19 vaccination adding to further turmoil around US vaccine policy and scientific transparency.

April 17, 2026 This week, a new commitment to expand the reach of lenacapavir for HIV PrEP is a step forward but not enough to deliver impact, detail on the proposed US budget cuts reflects a shift away from basic research, and a broader shift toward “trade over aid” raises new concerns for global health financing and impact.

April 14, 2026 In response to today’s announcement of the increased volume commitments for lenacapavir (LEN) for HIV prevention, AVAC and Access Bridge call for global leaders to do even more to ensure meaningful, expanded access.

April 14, 2026 Advocates are driving progress in HIV and STI prevention—guiding research, expanding access, holding powerful actors accountable and elevating community priorities. This roundup highlights advocacy in action, from new resources and policy frameworks to updates on the rollout of the latest prevention tools. Efforts are ramping up to roll out injectable LEN for PrEP amid new questions about pricing, volumes and supply timelines.